A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TEZEPELUMAB IN ADULT PARTICIPANTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (EMBARK)

Intervention/treatment:
TEZSPIRE
Medical condition:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Protocol code:
D5241C00006
Control number:
294109
Status:
Recruiting
Approved:
February 07, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06883305
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T3R 1W7
RECRUITING

British Columbia

Research Site
Vancouver, British Columbia, V5Z 1M9
RECRUITING

Ontario

Research Site
Ajax, Ontario, L1S 2J5
RECRUITING
Research Site
Burlington, Ontario, L7N 3V2
RECRUITING
Research Site
Scarborough Village, Ontario, M1P 2V5
RECRUITING
Research Site
Toronto, Ontario, M5T 3A9
WITHDRAWN
Research Site
Winchester, Ontario, K0C 2K0
RECRUITING
Research Site
Windsor, Ontario, N8X-5A6
RECRUITING

Quebec

Research Site
Montreal, Quebec, H1T 2M4
WITHDRAWN
Research Site
Montreal, Quebec, H3T 1E2
WITHDRAWN
Research Site
Québec, Quebec, G1G 3Y8
RECRUITING
Research Site
Québec, Quebec, G1V 4G5
RECRUITING
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4
RECRUITING
Research Site
Saint-Laurent, Quebec, H4R3C8
RECRUITING
Research Site
Trois-Rivières, Quebec, G8T 7A1
RECRUITING

Saskatchewan

Research Site
Saskatoon, Saskatchewan, S7N 0W8
NOT_YET_RECRUITING
Did you find what you were looking for?